Drug Profile

FL 101

Alternative Names: FL-101

Latest Information Update: 20 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Flame Biosciences
Developer Leap Therapeutics
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 1 beta inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Non-small cell lung cancer

Most Recent Events

17 Jan 2023 Flame Biosciences has been acquired and merged into Leap Therapeutics
27 May 2022 Flame Biosciences plans a phase 0 trial for Bladder Cancer (IV, Infusion), in August 2022 (NCT05395260)
05 May 2022 Flame Biosciences completes a phase I bioavailability trial (In volunteers) in USA (SC) (IV) (NCT04983732)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com